Kenneth Cornetta
Biochemistry, Genetics and Molecular Biology · Indiana University
Publications
294
Citations
11,985
Est. group size
—
Recurring co-author estimate
Active years
48
Publishing since 1979
Kenneth Cornetta studies gene therapy, focusing on using engineered viruses (such as lentiviral and AAV vectors) to deliver corrective genes into blood-forming stem cells to treat inherited diseases like sickle cell disease and immune deficiencies. A major part of the work involves developing methods to test the safety of these therapies, for example by tracking where the delivered genes insert into the genome and checking for contaminating viruses. The research also addresses making gene therapies accessible in low- and middle-income countries and related global health efforts.
Publication activity has been fairly steady, averaging around nine papers per year over the past five years, with a notable spike in 2023.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- Clinical Outcomes of Lentiviral Vector Gene Therapy for Sickle Cell Disease
Blood Advances · 2026
- Development of a Novel Method to Detect AAV Vector Integration
Viruses · 2026
- Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency
New England Journal of Medicine · 2025
- Modeling integration site data for safety assessment with MELISSA
Nature Communications · 2025
- Long-Term Follow-up of Hematopoietic Stem-Cell Gene Therapy for Adenosine Deaminase Deficiency
Transplantation and Cellular Therapy · 2025
- The translational gap for gene therapies in low- and middle-income countries
Science Translational Medicine · 2024
- Impact of training on knowledge, confidence and attitude amongst community health volunteers in the provision of community-based palliative care in rural Kenya
BMC Palliative Care · 2024
- Ex Vivo Lentiviral Hematopoietic Stem Cell (HSC) Gene Therapy May Represent a Curative Therapy for the Life-Threatening Inborn Error of Immunity Severe Combined Immunodeficiency Due to Adenosine Deaminase (ADA) Deficiency (ADA-SCID)
Blood · 2024
- Modeling integration site data for safety assessment with MELISSA
bioRxiv (Cold Spring Harbor Laboratory) · 2024
- Product Enhanced Reverse Transcriptase for Assessing Replication Competent Virus in Vectors Retroviral Vectors Pseudotyped with Galv and Vsv-G Envelopes
SSRN Electronic Journal · 2024
- Product Enhanced Reverse Transcriptase for assessing replication competent virus in vectors retroviral vectors pseudotyped with GALV and VSV-G envelopes
Journal of Virological Methods · 2024
- Telehospice for Cancer Patients Discharged from a Tertiary Care Hospital in Western Kenya
Journal of Pain and Symptom Management · 2023
- Implementation of a gene therapy education initiative by the ASGCT and Muhimbili University of Health and Allied Sciences
Molecular Therapy · 2023
- Supplementary Methods, Figure Legends, Table 1 from Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma
2023
- Supplementary Figure 2 from Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma
2023
- Molecular Therapy×7
- Blood×4
- Human Gene Therapy×3
- Journal of Pain and Symptom Management×3
- New England Journal of Medicine×2
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile